| abstract |
Disclosed herein are methods of treating diseases and disorders wherein inhibition of HDACs provides a benefit. In one embodiment of the present invention, the compound is (2E)-3-(2-ethyl-6-fluoro-3,4-dihydro-4-oxo-3-phenethylquinazoline- 7-yl)-N-hydroxyacrylamide or a salt thereof. In another embodiment of the present invention, the compound is (2E)-3-(2-ethyl-7-fluoro-3,4-dihydro-4-oxo-3-phenethylquinazoline ‑6‑yl)‑N‑hydroxyacrylamide, (2E)‑3‑(7‑chloro‑2‑ethyl‑3,4‑dihydro‑4‑oxo‑3‑phenethylquinazoline‑6 -yl)-N-hydroxyacrylamide or a salt thereof. In another aspect, the present invention relates to a composition comprising a therapeutically effective amount of the aforementioned compound or a pharmaceutically acceptable salt, solvate or hydrate, prodrug or metabolite thereof and a pharmaceutically acceptable Acceptable carrier or matrix. |